Overview
CGTX market data
Price History
CGTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.84 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.55 – $3.83 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $94M · P/B 3.48.
Company News
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) EstimateBenzinga · Aug 6, 2026, 9:13 PM
FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug ApplicationBenzinga · Jun 24, 2026, 11:45 AM
8-K filing — COGNITION THERAPEUTICS INC (CGTX)SEC EDGAR · Jun 24, 2026, 11:39 AM
Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of ZervimesineBenzinga · Jun 16, 2026, 11:40 AM
Cognition Therapeutics Discloses May 20 Meeting With FDA To Review Results From Its Phase 2 Study Of Zervimesine And Discuss Design And Endpoints Of A Study In Dementia With Lewy Bodies Patients With PsychosisBenzinga · May 21, 2026, 11:45 AM